The association between BMI and BRAFV600E mutation may differ by primary tumor size
in European Thyroid JournalSearch for other papers by Hyunju Park in
Current site
Google Scholar
PubMed
Search for other papers by Jung Heo in
Current site
Google Scholar
PubMed
Search for other papers by Hyun Jin Ryu in
Current site
Google Scholar
PubMed
Search for other papers by Min-Ji Kim in
Current site
Google Scholar
PubMed
Search for other papers by Young Lyun Oh in
Current site
Google Scholar
PubMed
Search for other papers by Tae hyuk Kim in
Current site
Google Scholar
PubMed
Search for other papers by Sun Wook Kim in
Current site
Google Scholar
PubMed
Search for other papers by Jae Hoon Chung in
Current site
Google Scholar
PubMed
Objective: Previous reports suggest that a high body mass index (BMI) increases the risk of thyroid carcinoma. However, it remains unclear whether a high BMI is associated with the risk of BRAFV600E mutation. We aimed to assess whether a high BMI is associated with an increased risk of BRAFV600E mutation.
Design and Methods: We screened 6,558 PTC patients who had undergone BRAFV600E mutation testing between January 2009 and December 2017. After exclusion, 6,438 PTC patients were enrolled. We used logistic regression, and restricted cubic spline plots of the adjusted odd ratios (ORs) were illustrated to model the relationship between BMI and BRAFV600E mutation.
Results: Among the 6,438 patients, 5,102 (79.2%) had the BRAFV600E mutation, and 4,954 (76.9%) were female. The median BMI was 23.8 (21.6 – 26.2) kg/m2. The primary tumor size was ≤ 1cm in 4,226 patients (65.6 %) and > 1cm in 2,212 patients (34.4 %). The BRAFV600E mutation was significantly associated with high BMI only in patients with primary tumor size > 1cm (OR 1.034; 95% CI 1.003 – 1.065; P = 0.029), whereas no clear association was found in patients with primary tumor size ≤ 1cm (OR 1.007; 95% CI 0.984 – 1.030; P = 0.570). Gender was not a significant factor in either group.
Conclusions: Our study found that a higher BMI was positively associated with BRAFV600E mutation in patients with primary tumor size > 1cm. These results suggest that the association between BMI and BRAFV600E mutation status differs depending on primary tumor size.
European Thyroid Journal is committed to supporting researchers in demonstrating the impact of their articles published in the journal.
As an open-access journal, European Thyroid Journal articles are immediately available to read on publication, without restriction. The two types of article metrics we measure are (i) more traditional full-text views and pdf downloads, and (ii) Altmetric data, which shows the wider impact of articles in a range of non-traditional sources, such as social media.
More information is on the Reasons to publish page.
| Jan 2022 onwards | Past Year | Past 30 Days | |
|---|---|---|---|
| Full Text Views | 239 | 239 | 239 |
| PDF Downloads | 117 | 117 | 117 |
Online ISSN: 2235-0802
Print ISSN: 2235-0640
Strengthening biomedical communities
to advance science and health
CONTACT US
Bioscientifica Ltd | Starling House | 1600 Bristol Parkway North | Bristol BS34 8YU | UK
Bioscientifica Ltd | Registered in England no 3190519